Regeneron Pharmaceuticals Stock Forecast
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
REGN analyst consensus
Consensus (27 analysts)
buy
Avg. price target
$856.23+15.38%
- Strong buy 4
- Buy 14
- Hold 8
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 27 Wall Street analysts covering Regeneron Pharmaceuticals (2026-10-07), 18 rate the stock a buy or strong buy, 8 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $856.23, with a high estimate of $1,030.00 and a low estimate of $730.00. The average target implies upside of 15.4% from the current price of $742.12.
The spread between the highest and lowest targets is 41.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for REGN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 15% |
| Buy | 14 | 52% |
| Hold | 8 | 30% |
| Sell | 0 | 0% |
| Strong sell | 1 | 4% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $730.00 | -1.63% |
| Average target | $856.23 | +15.38% |
| High target | $1,030.00 | +38.79% |